Voyager Therapeutics News

Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast

LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fi

Voyager TherapeuticsMay 6 00:00 ET

Oppenheimer Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)

TipRanksMay 1 07:55 ET

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Not Doing Enough For Some Investors As Its Shares Slump 26%

Voyager Therapeutics, Inc. (NASDAQ:VYGR) shares have had a horrible month, losing 26% after a relatively good period beforehand. Longer-term shareholders will rue the drop in the share price, since

Simply Wall StApr 26 06:06 ET

Express News | Voyager Therapeutics To Present Translational Data For IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials At ASGCT 27th Annual Meeting

Moomoo 24/7Apr 22 16:31 ET

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

- Spotlight on new, second-generation, TRACER-derived AAV capsids; translatability as evidenced by cross-species and receptor data; and activity against therapeutic targets in Alzheimer's disease and

Voyager TherapeuticsApr 22 00:00 ET

Optimistic Buy Rating for Voyager Therapeutics Amid Strong Pipeline and Strategic Partnerships

TipRanksApr 17 05:07 ET

Express News | Selection Of The Development Candidate Triggered A $3M Milestone Payment To Voyager, Which The Company Expects To Receive In Q2 Of 2024

Moomoo 24/7Apr 16 07:12 ET

Express News | Voyager Therapeutics And Neurocrine Biosciences Expect To File An FDA Investigational New Drug Application For GBA1 Program Candidate In 2025

Moomoo 24/7Apr 16 07:07 ET

Express News | Voyager Therapeutics And Neurocrine Biosciences Have Selected Lead Development Candidate In GBA1 Gene Therapy Program For Potential Treatment Of Parkinson's Disease And Other GBA1-mediated Diseases

Moomoo 24/7Apr 16 07:06 ET

Express News | Voyager Therapeutics:Eligible to Receive Additional Future Development & Commercialization Milestone Payments Based on Further Advancement of Program

Moomoo 24/7Apr 16 07:03 ET

Express News | Voyager Therapeutics : Selection of Development Candidate Triggered a $3 Mln Milestone Payment to Voyager, Expects to Receive in Q2 of 2024

Moomoo 24/7Apr 16 07:03 ET

Express News | Voyager Therapeutics Inc: Expect to File an Investigational New Drug (Ind) Application With FDA for Program in 2025

Moomoo 24/7Apr 16 07:02 ET

Express News | Voyager Therapeutics Announces Selection of Development Candidate for Gba1 Program in Collaboration With Neurocrine Biosciences, Triggering Milestone Payment

Moomoo 24/7Apr 16 07:00 ET

Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration With Neurocrine Biosciences, Triggering Milestone Payment

LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint

Voyager TherapeuticsApr 16 00:00 ET

Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Yahoo FinanceApr 9 14:46 ET

Voyager Therapeutics Said Co And CFO Peter P. Pfreundschuh Entered Into A Transition, Separation And Release Of Claims Agreement; Pfreundschuh Resigned From His Position AsCFO Effective On April 12, 2024

Voyager Therapeutics Said Co And CFO Peter P. Pfreundschuh Entered Into A Transition, Separation And Release Of Claims Agreement; Pfreundschuh Resigned From His Position AsCFO Effective On April 12, 2

BenzingaApr 2 16:36 ET

Voyager Therapeutics Announces CFO Transition Plan and Appointment

TipRanksApr 2 16:24 ET

Is Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Latest Stock Performance A Reflection Of Its Financial Health?

Voyager Therapeutics' (NASDAQ:VYGR) stock is up by a considerable 17% over the past three months. Given that the market rewards strong financials in the long-term, we wonder if that is the case in t

Simply Wall StApr 2 06:41 ET

Buy Voyager Stock, Analyst Says. The Little Biotech Could Have Big Breakthroughs. -- Barrons.com

Voyager Therapeutics has surely tried investors' patience since it came public eight years ago. The biotech firm's stock has fallen as low as $2.50 from a peak of $30, as its early programs to treat neurological diseases didn't pan out.

Barron'sMar 30 03:00 ET

Express News | Voyager Therapeutics Shares Are Trading Higher After Guggenheim Initiated Coverage on the Stock With a Buy Rating and a Price Target of $22

Moomoo 24/7Mar 26 07:12 ET